A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Hip.

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Hip.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Nov 2010 The tanezumab osteoarthritis clinical program is currently on hold due to potential adverse reactions leading to joint replacement.
    • 10 Nov 2010 Results reported in a Late-Breaking Abstract Session at the 2010 ACR/ARHP Annual Scientific Meeting.
    • 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top